Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sinovac Biotech
Thumbnail
March 11, 2022

Another strike for biotech: China

Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.

Thumbnail
December 31, 2021

Covid-19 developments over the Christmas period

Drug makers and regulators take aim at Omicron.

Article image
Vantage logo
September 20, 2021

Pfizer/Biotech's Covid vaccine data looks good enough for FDA, but parents?

Article image
Vantage logo
March 31, 2021

Pfizer’s Covid paediatric jab needs to win in the home as well as the clinic

Article image
Vantage logo
February 18, 2021

How low can you go in Covid-19 vaccine trials?

Article image
Vantage logo
January 14, 2021

J&J provides early hope for single-dose Covid-19 vaccine

Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.

Article image
Vantage logo
October 13, 2020

J&J pause adds to adenovirus vaccine doubts

Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.

Article image
Vantage logo
September 14, 2020

Upsizing and restarts: Covid vaccine trials rumble on

Article image
Vantage logo
September 09, 2020

Covid vaccine developers face nervous wait

More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.

Article image
Vantage logo
June 04, 2020

Have Glaxo and Sanofi been snubbed by Project Warp Speed?

Article image
Vantage logo
May 19, 2020

Moderna reminds the markets of biotech’s dual purpose

On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.

Open modal